Skip to content

XOMA Corporation XOMA EBITDA margin

EBITDA margin at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
46.6%+37.6pp
Royalty Pharma logo
Royalty PharmaRPRX
57.1%-6.3pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
2.7%+1.4pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
44.4%-11.9pp
Zymeworks logo
ZymeworksZYME
-132.6%+10.5pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-78.7%-2.1pp

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+152%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

Based on trailing twelve months.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's EBITDA margin?
XOMA Corporation (XOMA) reported EBITDA margin of 17.1% in Q1 2026.
How has XOMA Corporation's EBITDA margin changed year-over-year?
XOMA Corporation's EBITDA margin increased by 127.8% year-over-year, from -61.4% to 17.1%.
What is the long-term trend for XOMA Corporation's EBITDA margin?
Over 4 years (2020 to 2025), XOMA Corporation's EBITDA margin has grown at a -10.2% compound annual growth rate (CAGR), from 42.3% to 27.5%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.